双歧杆菌四联活菌片联合美沙拉嗪治疗溃疡性结肠炎患者的效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Bifidobacterium Quadruple Live Tablets combined with Mesalazine on serum C-reactive protein (CRP) levels and adverse reactions in patients with ulcerative colitis (UC).Methods Eightysix patients with UC admitted to our hospital from January 2016 to September 2019 were enrolled in the study.They were divided into control group and observation group according to the random number table method, 43 cases in each group.The control group was treated with Mesalazine Enteric-Coated Tablets orally；the observation group was treated with Mesalazine Enteric-Coated Tablets and Bifidobacterium Quadruple Live Tablets；the patients in both groups were given continuous medication for 2 months.The treatment efficiency, c-reactive protein (CRP), interleukin-4 (IL-4), interleukin-8 (IL-8) index, disease activity index (Mayo) score, and adverse reactions were compared between the two groups.Results After 2 months of treatment, the effective rate of treatment in the observation group (95.35%) was higher than that in the control group (79.07%), and IL-4 (1.38±0.28) ng/ml was higher than that the control group for(0.94±0.31) ng/ml, CRP (7.85±2.74) mg/L, IL-8 index (17.64±4.59) μg/L, were lower than those of the control group(13.68±3.62) mg/L, (25.54±5.87) μg/L, Mayo score (3.42±0.44), and adverse reaction rate (6.98%) were lower than that in the control group for (5.84±0.38), the tatal of incidence of aduorse reactions (6.98%) was lower than that of the control group (25.58%), the differences were statistically significant (P＜0.05).Conclusion Bifidobacterium Quadruple Live Tablets combined with Mesalazine can effectively treat UC.It has synergistic therapeutic effect, can improve the treatment efficiency, regulate the levels of CRP, IL-4 and IL-8, and improve the immune function of the body, reducing the occurrence of adverse reactions, high safety, and huge prospects for clinical application, it is worth promoting.

Key words： Ulcerative colitis Bifidobacterium Quadruple Live Bacteria Tablets Mesalazine C-reactive protein Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HOU Jing
	ZHU Mei-ling
	LI Yun-hong

Cite this article:

HOU Jing,ZHU Mei-ling,LI Yun-hong. Effect of Bifidobacterium Tetrad combined with Mesalazine in the treatment of ulcerative colitis[J]. 中国当代医药, 2020, 27(11): 59-62.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I11/59

[1]	王欣，陈爱霞，王佳，等.平溃健脾汤联合美沙拉嗪在溃疡性结肠炎治疗中的应用[J].山东医药，2018，58（26）：44-46.
[2]	刘兴.双歧杆菌四联活菌联合美沙拉嗪治疗溃疡性结肠炎的临床疗效观察[J].中国现代药物应用，2018，12（4）：107-108.
[3]	李芳，周云仙.炎症型肠炎发病危险因素分析[J].浙江临床医学，2019，21（3）：336-338.
[4]	乐琴琴.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的疗效分析[J].中国基层医药，2018，25（10）：1249-1252.
[5]	招杰.益生菌治疗溃疡性结肠炎效果观察与研究[J].中国实用医药，2018，13（1）：84-85.
[6]	李铭.美沙拉嗪联合双歧杆菌四联活菌片治疗溃疡性结肠炎临床研究[J].数理医药学杂志，2018，31（11）：114-115.
[7]	中华医学会消化病学分会炎症性肠病协作组.中国炎症性肠病诊断治疗规范的共识意见[J].中华内科杂志，2008，47（1）：73-79.
[8]	谭文凯.双歧杆菌联合美沙拉嗪与单用美沙拉嗪治疗轻中度溃疡性结肠炎临床观察[J].锦州医科大学学报，2017，38（3）：21-23.
[9]	韩丹，孙宏文.双歧杆菌治疗溃疡性结肠炎的作用机制研究进展[J].现代中西医结合杂志，2019，28（20）：2268-2271.
[10]	王友多，陈华.美沙拉嗪联合双歧杆菌四联活菌治疗活动期溃疡性结肠炎的临床观察[J].中国药房，2016，27（3）：326-328.
[11]	方木林.双歧三联活菌胶囊联合美沙拉嗪对溃疡性结肠炎患者肠道微生态影响[J].中国微生态学杂志，2018，30（3）：330-332.
[12]	阮瑞华.双歧杆菌四联活菌联合美沙拉嗪治疗溃疡性结肠炎的效果和安全性分析[J].河南医学研究，2017，26（11）：2045-2046.
[13]	余海平，李春耕.双歧杆菌三联活菌片联合美沙拉嗪对溃疡性结肠炎患者免疫功能及肠黏膜屏障功能的影响[J].现代中西医结合杂志，2018，27（29）：36-39.
[14]	薄茂林，薛芝兰，张涛.3种益生菌制剂联合美沙拉嗪口服治疗轻中度溃疡性结肠炎疗效[J].武警医学，2017，28（10）：980-984.
[15]	岳原亦，张强，林连捷，等.双歧杆菌四联活菌片联合美沙拉嗪对轻中度溃疡性结肠炎的疗效观察[J].实用药物与临床，2017，20（5）：517-520.
[16]	田琰.美沙拉嗪联合双歧杆菌四联活菌治疗溃疡性结肠炎[J].安徽卫生职业技术学院学报，2016，15（3）：46-47.
[17]	葛洋，赵绍林，杨栋，等.黄芪颗粒联合双歧杆菌四联活菌片治疗溃疡性结肠炎的疗效分析[J].重庆医学，2019，48（8）：1359-1362.